Standard BioTools Inc (LAB) FinancialsLABFinancialStandard BioTools Inc

Standard BioTools Inc. (LAB) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Consumables, accounting for 46.7% of total sales, equivalent to $9.38M. Other significant revenue streams include Services and other revenue and Instruments. Understanding this composition is critical for investors evaluating how LAB navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Standard BioTools Inc. maintains a gross margin of 52.40%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -38.94%, while the net margin is -107.07%. These profitability ratios, combined with a Return on Equity (ROE) of -11.18%, provide a clear picture of how effectively LAB converts its operational activities into shareholder value.

In the context of the broader market, LAB competes directly with industry leaders such as OSUR and ELMD. With a market capitalization of $252.00M, it holds a significant position in the sector. When comparing efficiency, LAB's gross margin of 52.40% stands against OSUR's 43.46% and ELMD's 78.71%. Such benchmarking helps identify whether Standard BioTools Inc. is trading at a premium or discount relative to its financial performance.

LAB has shown significant revenue fluctuations, with total revenue for Q2 2026 at $20,104,000, but it reported a net income loss of $26,758,000. The gross margin has been relatively stable, around 52.40% in Q2 2026, but the company has struggled with profitability, as indicated by a net margin of -107.07%.